Get the Stockscreener App
16.05
5.52%
0.84
Pre-market:
16.05
Eton Pharmaceuticals Inc stock is traded at $16.05, with a volume of 464.15K.
It is up +5.52% in the last 24 hours and up +3.82% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$15.21
Open:
$15.3
24h Volume:
464.15K
Relative Volume:
1.86
Market Cap:
$430.42M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-61.73
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
+8.81%
1M Performance:
+3.82%
6M Performance:
-5.87%
1Y Performance:
-7.06%
1-Day Range:
$15.07
$16.36
1-Week Range:
$14.27
$16.36
52-Week Range:
$11.09
$23.00
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
16.05 | 407.89M | 31.38M | -6.69M | -1.84M | -0.26 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Analysts - MarketBeat
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM) - The Globe and Mail
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug By Investing.com - Investing.com South Africa
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug - Investing.com
Eton Pharmaceuticals Licenses US Marketing Rights to Ultra-Rare Disease Product - marketscreener.com
Eton Pharmaceuticals licenses ultra-rare disease treatment candidate - Investing.com
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - The Manila Times
Eton Pharmaceuticals Licenses U.S. Marketing Rights for Ultra-Rare Disease Product Candidate, Anticipates FDA Approval by Mid-2026 - Quiver Quantitative
Aug Drivers: What drives Eton Pharmaceuticals Incs stock priceJuly 2025 Macro Moves & Real-Time Volume Analysis - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Unraveling the 96.72% Potential Upside for Investors - DirectorsTalk Interviews
Breakout Zone: Is Eton Pharmaceuticals Inc a defensive stockQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (ETON) Investor Outlook: Unpacking The 96% Upside Potential - DirectorsTalk Interviews
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth (NASDAQ:ETON) - Seeking Alpha
Geopolitics Watch: Can Eton Pharmaceuticals Inc maintain sales growthWatch List & Low Risk High Reward Ideas - baoquankhu1.vn
Insider Favorites: 3 Growth Stocks With Strong Ownership - simplywall.st
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
(ETON) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Exploring A Potential 94.68% Upside - DirectorsTalk Interviews
US Market Wrap: Can Eton Pharmaceuticals Inc maintain sales growthJuly 2025 Weekly Recap & Daily Stock Trend Reports - baoquankhu1.vn
Death Cross: Why Eton Pharmaceuticals Inc stock remains a top recommendationJuly 2025 Review & Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Layoff Watch: Why is Eton Pharmaceuticals Inc stock going down2025 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Potential Upside of Over 81% in the Rare Disease Sector - DirectorsTalk Interviews
Can Eton Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Retail & Weekly High Momentum Picks - Улправда
Why Eton Pharmaceuticals Inc. stock could rally in 20252026 world cup usa national team group stage playmakers transition play group prediction analysis - Улправда
How (ETON) Movements Inform Risk Allocation Models - Stock Traders Daily
Eton Pharmaceuticals (NASDAQ:ETON) Upgraded at Zacks Research - Defense World
Dental EconomicsEton Pharmaceuticals, Inc.Common Stock (Nasdaq:ETON) Stock Quote - FinancialContent
FDA extends target action date for Eton's ET-400 - MSN
Those who invested in Eton Pharmaceuticals (NASDAQ:ETON) three years ago are up 483% - Yahoo Finance
B. Riley Securities Initiates Coverage of Eton Pharmaceuticals (ETON) with Buy Recommendation - MSN
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Is Eton Pharmaceuticals Inc. stock positioned for long term growth2025 Key Lessons & Growth Oriented Trading Recommendations - Улправда
What makes Eton Pharmaceuticals Inc. stock attractive to growth fundsWeekly Stock Report & Weekly High Conviction Ideas - Улправда
Eton Pharmaceuticals, Inc.(NasdaqGM: ETON) added to NASDAQ Biotechnology Index - marketscreener.com
Stock Market Recap: Why Eton Pharmaceuticals Inc. stock could rally in 2025July 2025 Institutional & Reliable Price Action Trade Plans - moha.gov.vn
Will Eton Pharmaceuticals Inc. stock beat EPS estimatesEarnings Beat & Verified Chart Pattern Signals - Улправда
Published on: 2025-12-20 13:06:24 - Улправда
Why Eton Pharmaceuticals Inc. stock could be next big winnerWeekly Trade Summary & Safe Entry Zone Identification - Улправда
Will Eton Pharmaceuticals Inc. stock maintain momentum in 2025Portfolio Gains Report & Free Weekly Watchlist of Top Performers - Bölüm Sonu Canavarı
Can Eton Pharmaceuticals Inc. stock continue upward trendProfit Target & Fast Momentum Stock Entry Tips - DonanımHaber
How Eton Pharmaceuticals Inc. stock trades before earningsJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - DonanımHaber
Published on: 2025-12-19 10:25:25 - Улправда
AI Stocks: Why Eton Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Chart Watch & Consistent Return Investment Signals - Улправда
Aug Big Picture: Why Eton Pharmaceuticals Inc. stock could rally in 2025Profit Target & Stepwise Trade Signal Guides - Улправда
Analysts’ Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON) - The Globe and Mail
Highlighting December 2025's Growth Leaders With Insider Ownership - simplywall.st
(ETON) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Eton Pharmaceuticals (NASDAQ:ETON) Downgraded by Wall Street Zen to Hold - Defense World
Eton Pharmaceuticals, Inc. (ETON) CCO records 85-share tax withholding transaction - Stock Titan
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):